ADC Therapeutics SA, a leader in the field of antibody drug conjugates, has announced a new compensation agreement for a recently hired employee. The company has granted options to purchase 17,000 common shares as an inducement for employment, approved by the Compensation Committee under the Inducement Plan. These options will vest 25% after one year, with the remainder vesting monthly over the following three years, contingent on continued employment. This move aligns with ADC Therapeutics' commitment to rewarding its workforce through strategic grants.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。